Avandia Advisory Cmte. Could Be Observational Data’s Coming Out Party
Executive Summary
The recommendations from FDA's joint advisory committee review of a signal of potential cardiovascular risk for GlaxoSmithKline's type 2 diabetes therapy Avandia (rosiglitazone) will likely be determined by how much weight the panel gives to meta-analysis as a means of assessing a drug's safety
You may also be interested in...
Advisory Cmte. Conflict of Interest Waivers Common; Avandia Is High Water Mark
As currently convened, the majority of FDA advisory committee meetings on drugs would likely violate a limit on participation by experts with a financial conflict of interest being considered by Congress
Advisory Cmte. Conflict of Interest Waivers Common; Avandia Is High Water Mark
As currently convened, the majority of FDA advisory committee meetings on drugs would likely violate a limit on participation by experts with a financial conflict of interest being considered by Congress
FDA Not Saying What House Democrats Want To Hear
Henry Waxman and House Democrats held an Oversight and Government Reform Committee meeting on GlaxoSmithKline's Avandia to highlight the need to stronger postmarketing oversight FDA.